NovaBridge Biosciences (NBP) News & EventsNBPNovaBridge Biosciences

NovaBridge Appoints Srishti Gupta as CEO

NovaBridge announced the appointment of Srishti Gupta as CEO and a member of the company's board of directors, effective July 1. Xi-Yong Fu will step down as CEO to pursue other opportunities. Fu will support the company in an advisory capacity during the transition. Most recently, Gupta served as CEO of Idorsia.

NovaBridge Biosciences Secures FDA Support for Givastomig Accelerated Approval

The company states: "NovaBridge Biosciences announced that based on a productive Type B meeting with the U.S. Food and Drug Administration and receipt of written minutes, NovaBridge has secured FDA alignment on givastomig's potential eligibility for an accelerated approval pathway in 1L Her2-, CLDN 18.2+, PD-L1+ GEC patients, building on positive data from the Phase 1b combination trial. The Company intends to initiate a registrational Phase 3 trial, in combination with immunochemotherapy, as early as Q4 2026. Final study design details will be discussed with FDA."

NovaBridge Reports Positive Phase 2a Results for VIS-101

NovaBridge Biosciences, a global biotechnology platform company committed to accelerating access to innovative medicines, and its subsidiary, Visara announced topline results from the Phase 2a study of VIS-101. VIS-101 produced rapid and robust efficacy, and durable treatment responses with both 3 mg and 6 mg dose cohorts: Mean improvement in Best Corrected Visual Acuity of greater than10 Early Treatment of Diabetic Retinopathy Study letters; Median central subfield thickness reduction of 100-150 mm; Potential best-in-class durability with: two thirds of patients retreatment-free at 4 months, half of patients retreatment-free at 6 months; Favorable safety and no dose limited toxicity